-
CT colonographic screening of asymptomatic adults identified 90% of polyps or cancers measuring 10 mm or more.
-
Homocysteine (HCYS) has all the trappings of a first-rate cardiovascular risk factor: as strong an association with CVD endpoints as cholesterol, ease of identification, and simplicity of modulation. Trouble is, trials to date have been unable to show that reductions of homocysteine provide meaningful benefits to patients.
-
Intensive hemoglobin A1c lowering does not reduce the rate of cardiovascular death, and results in an increase in hypoglycemic events.
-
-
Lifestyle changes plus red yeast rice and fish oil resulted in similar beneficial effects on LDL cholesterol as moderate-dose statin therapy in patients meeting criteria for drug therapy for high LDL cholesterol.
-
Optimizing medical and lifestyle change therapy rather than performing PCI is appropriate as the initial management strategy for most patients with known CAD who do not have unstable or disabling symptoms.
-
There are no disease-modifying pharmacotherapies for COPD. That is, although bronchodilators, anticholinergic agents, and inhaled corticosteroids improve FEV1 and reduce symptoms, decline in pulmonary function continues unabated and lung function returns promptly to pretreatment status once medication is stopped.
-
A randomized controlled trial in the Netherlands showed that oral prednisolone and naproxen were equivalent in the treatment of acute gout with no difference in side effects.
-
Strategies to determine treatment of acute coronary syndromes need to take gender into account.
-
Using blood pressure, BUN, serum sodium, and presence of peripheral arterial disease as predictors of mortality in heart failure patients, 67% who had 3 or more factors died within 6 months and would qualify for the Medicare hospice benefit.
